Argatroban versus Lepirudin in critically ill patients (ALicia): a randomized controlled trial |
| |
Authors: | Tanja A Treschan Maximilian S Schaefer Johann Geib Astrid Bahlmann Tobias Brezina Patrick Werner Elisabeth Golla Andreas Greinacher Benedikt Pannen Detlef Kindgen-Milles Peter Kienbaum Martin Beiderlinden |
| |
Affiliation: | .Department of Anaesthesiology, Duesseldorf University Hospital, Heinrich-Heine University Duesseldorf, Moorenstrasse 5, 40225 Duesseldorf, Germany ;.Institut für Immunologie und Transfusionsmedizin, Ernst-Moritz-Arndt Universität Greifswald, Sauerbruchstrasse, 17489 Greifswald, Germany ;.Department of Anaesthesiology, Marienhospital Osnabrück, Bischofsstraße 1, 49074 Osnabrueck, Germany |
| |
Abstract: |
IntroductionCritically ill patients often require renal replacement therapy accompanied by thrombocytopenia. Thrombocytopenia during heparin anticoagulation may be due to heparin-induced thrombocytopenia with need for alternative anticoagulation. Therefore, we compared argatroban and lepirudin in critically ill surgical patients.MethodsFollowing institutional review board approval and written informed consent, critically ill surgical patients more than or equal to 18 years with suspected heparin-induced thrombocytopenia, were randomly assigned to receive double-blind argatroban or lepirudin anticoagulation targeting an activated Partial Thromboplastin Time (aPTT) of 1.5 to 2 times baseline. In patients requiring continuous renal replacement therapy we compared the life-time of hemodialysis filters. We evaluated in all patients the incidence of bleeding and thrombembolic events.ResultsWe identified 66 patients with suspected heparin-induced thrombocytopenia, including 28 requiring renal replacement therapy. Mean filter lifetimes did not differ between groups (argatroban 32 ± 25 hours (n = 12) versus lepirudin 27 ± 21 hours (n = 16), mean difference 5 hours, 95% CI −13 to 23, P = 0.227). Among all 66 patients, relevant bleeding occurred in four argatroban- versus eleven lepirudin-patients (OR 3.9, 95% CI 1.1 to 14.0, P = 0.040). In the argatroban-group, three thromboembolic events occurred compared to two in the lepirudin group (OR 0.7, 95% CI 0.1 to 4.4, P = 0.639). The incidence of confirmed heparin-induced thrombocytopenia was 23% (n = 15) in our study population.ConclusionsThis first randomized controlled double-blind trial comparing two direct thrombin inhibitors showed comparable effectiveness for renal replacement therapy, but suggests fewer bleeds in surgical patients with argatroban anticoagulation.Trial registrationClinical Trials.gov {"type":"clinical-trial","attrs":{"text":"NCT00798525","term_id":"NCT00798525"}}NCT00798525. Registered 25 November 2008Electronic supplementary materialThe online version of this article (doi:10.1186/s13054-014-0588-8) contains supplementary material, which is available to authorized users. |
| |
Keywords: | |
本文献已被 SpringerLink 等数据库收录! |
|